Search Results | Showing 51 - 60 of 90 results for "Sciences" |
| | | ... compensation payments. "Traditional methods of equity investing are being reshaped by massive advances in technology and data sciences. At the same time, client preferences are shifting, focusing not just on outcomes but on how both performance and fees ... |
| | | | ... the government's $500 million Biomedical Translation Fund (BTF). Brandon Capital will drive the development of its life sciences fund, the Medical Research Commercialisation Fund, as part of a government initiative to make Australia a global leader in ... |
| | | | ... capital investment and foreign interest. Sauer said: "Sectors traditionally attractive to venture capital, such as life sciences and information and communication technology, will continue to grow due to increased capital availability and support courtesy ... |
| | | | A number of institutional investors are proving the health sciences venture capital space holds significant potential for Australian investors, with funding from the likes of QIC and Hostplus driving major pharmaceutical developments. According to data ... |
| | | | ... In the 2015 financial year, $46 million was invested by venture capital funds into the Australian healthcare and life sciences sector. |
| | | | ... metropolitan areas which are seen as 'innovation centres' for technology, finance, media, education, and the medical sciences, attracting younger employees and "establishing a self-sustaining base of knowledge-based growth." Likewise, growth in the Asia-Pacific ... |
| | | | ... partner at CM Capital Investments, an institutionally backed venture capital company focused on the biotechnology, life sciences, telecommunications, information technology and renewable energy sectors. He has held directorships on numerous companies ... |
| | | | ... the opportunity for institutions is being overlooked. The Australian Bureau of Agricultural and Resource Economics and Sciences (ABARES) also forecasts farm production value will rise by 3% in 2016-17, following a 9% increase this financial year to $58.7 ... |
| | | | ... research will come to the fore through a partnership announced by Findex and the Australian Academy of Health and Medical Sciences. The partnership will discuss potential recommendations to the federal government's Medical Research Future Fund - a perpetual ... |
| | | | ... an illegal substance." Ariel holds between 75 and 90 stocks in its portfolio, with the top allocations going to Gilead Sciences, Microsoft, China Mobile and GlaxoSmithKline. It has delivered a return on equity of 21.5% over the five years to 30 June ... |
|